Polymorphism of DNA repair genes<i>OGG1, XRCC1, XPD</i>and<i>ERCC6</i>in bladder cancer in Belarus

Ramaniuk, Volha P.; Никитченко, Н. В.; Савина, Н. В.; Kuzhir, Tatyana D.; Rolevich, A.I.; Krasny, S.; Sushinsky, Vadim E.; Гончарова, Р. И.

doi:10.3109/1354750x.2014.943291

Cited by 25 publications

(22 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liu et al (20) also revealed that the DNA repair gene ERCC6 rs1917799 polymorphism is associated with gastric cancer risk in the Chinese population. It has also been identified that ERCC6 polymorphisms are associated with susceptibility to oral, lung, bladder and colorectal cancers (21)(22)(23). These findings suggested that ERCC6L may act as an oncogene involved in tumor progression, and may be considered a potential target to aid the efficient diagnosis and development of therapies against breast cancer.…”

Section: Discussionmentioning

confidence: 96%

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

et al. 2018

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease with a high degree of diversity with regards to tumor histological stage and molecular subtypes. These heterogeneous characteristics determine the risk of disease progression and therapeutic resistance. Understanding tumor heterogeneity is of primary concern to identify and develop novel and specific potential targets for diagnosis and therapy. The present study analyzed 106 paired breast cancer tissues from The Cancer Genome Atlas and demonstrated that excision repair cross‑complementation group 6 like (ERCC6L), a newly discovered DNA helicase, was overexpressed in 91.51% (97/106), unchanged in 7.54% (8/106) and decreased in 0.94% (1/106) of breast cancer samples. A short hairpin RNA ERCC6L lentivirus was constructed to investigate the role of ERCC6LR in cancer. First, a Celigo Image Cytometry system was used to detect MDA‑MB‑231 cell growth number following transfection with shERCC6L‑lentivirus or NC‑lentivirus and it was identified that the growth number of fluorescent MDA‑MB‑231 cells post‑transduction with shERCC6L‑lentivirus was decreased compared with the cells transduced with NC‑lentivirus. Then, the effect of knockdown of ERCC6L expression on the cell cycle distribution and apoptosis was to analyzed using fluorescence‑activated cell sorting (FACS). The FACS data demonstrated that knockdown of ERCC6L expression levels in MDA‑MB‑231 cells significantly increased S phase population but decreased the G1 and G2/M phase populations compared with the NC group. The apoptosis rate of MDA‑MB‑231 cells post‑transduction with shERCC6L‑lentivirus for 5 days was increased to 12.16±0.146% compared with the negative control rate (4.86±0.204%). These functional studies demonstrated that knockdown of ERCC6L expression levels in MDA‑MB‑231 cells significantly inhibited breast cancer cell proliferation, disturbed cell cycle distribution and induced apoptosis in vitro. These findings suggested that ERCC6L, which is highly expressed in breast cancer, acts as an oncogene, is involved in breast cancer development and may serve as a novel molecular target for the treatment of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 96%

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The rs13181 polymorphism of ERCC2 is a T to G substitution at the 751 locus, which may alter the enzymatic activity of the encoded protein. ERCC2 rs13181 is associated with various cancers, such as gastric cancer, esophageal cancer, non-small cell lung cancer, hepatocellular carcinoma, prostate cancer, skin cancer, and bladder cancer (Yin et al, 2013;Zhu et al, 2013;Li et al, 2014;Ramaniuk et al, 2014;Zhu et al, 2014;Yang et al, 2015;Guo et al, 2015). Previous studies have reported the association between the ERCC2 rs13181 polymorphism and glioma development, but the results are inconclusive (Caggana et al, 2001;Wrensch et al, 2005;Yang et al, 2005;Liu et al, 2009;Luo et al, 2013;Rodriguez-Hernandez et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

ERCC2 rs13181 polymorphism association with glioma susceptibility in a Chinese population

Gao

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a case-control study to investigate the role of ERCC2 rs13181 polymorphism in glioma development. A total of 165 patients who were histopathologically diagnosed to have gliomas and 330 controls were collected at Jiujiang First People's Hospital between July 2012 and June 2014. The ERCC2 rs13181 polymorphism was analyzed using a polymerase chain reaction -restriction fragment length polymorphism assay. By conditional regression analysis, we found that the GG genotype of the ERCC2 rs13181 polymorphism is associated with susceptibility to gliomas when compared to the TT genotype (OR = 2.05, 95%CI = 1.11-3.79). In the recessive model, the GG genotype is associated with an increased risk of gliomas when compared with the TT+TG genotype (OR = 1.87, 95%CI = 1.03-3.37). In conclusion, the ERCC2 rs13181 polymorphism is correlated with an increased risk of gliomas in codominant and recessive models, which suggests that this polymorphism could influence the etiology of gliomas.

show abstract

“…During the extraction of the data, 4 studies were excluded because of insufficient data (10,11), overlapping data (12) or irrelevance to ERCC6 Met1097Val and Arg1230Pro polymorphisms (13). Ultimately, 5 independent studies, including 4 European studies and 1 Asian study, were selected for the meta-analysis (14)(15)(16)(17)(18). All studies were consistent with HWE.…”

Section: Study Characteristicsmentioning

confidence: 99%

Meta-Analysis Reveals no Significant Association between ERCC6 Polymorphisms and Bladder Cancer Risk

Zhou

Li³

et al. 2017

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

Polymorphism of DNA repair genesOGG1, XRCC1, XPDandERCC6in bladder cancer in Belarus

Abstract: Among four DNA repair gene polymorphisms, the OGG1 326 Ser/Cys and XPD 312 Asp/Asn heterozygous genotypes might be recognized as potential genetic markers modifying susceptibility to bladder cancer in Belarus.

Cited by 25 publications

References 61 publications

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth

ERCC2 rs13181 polymorphism association with glioma susceptibility in a Chinese population

Meta-Analysis Reveals no Significant Association between ERCC6 Polymorphisms and Bladder Cancer Risk

Contact Info

Product

Resources

About